Condition: Metastatic Colorectal Cancer · Sponsor: Centre Hospitalier Universitaire de Besancon
This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma
This description comes directly from the study's public registry record.
Angélique VIENOT, MD, PhD · 00 33 3 81 47 99 99 · angelique.vienot@gmail.com
Christophe BORG, MD, PhD · 00 33 3 81 47 99 99 · xtoph.borg@gmail.com
Always discuss trial participation with your own doctor first.
| CHU de Besançon | Besançon, France | Recruiting |
| CHU Estain | Clermont-Ferrand, France | Not Yet Recruiting |
| Hôpital Henri Mondor | Créteil, France | Recruiting |
| Centre Georges François Leclerc | Dijon, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Not Yet Recruiting |
| Hôpital Privé Jean Mermoz | Lyon, France | Recruiting |
| Hôpital Nord Franche Comté | Montbéliard, France | Recruiting |
| CHU Montpellier | Montpellier, France | Recruiting |
| Groupe hospitalier de la région de Mulhouse et Sud Alsace | Mulhouse, France | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Not Yet Recruiting |
| Hôpital Européen Georges Pompidou | Paris, France | Recruiting |
| Hôpital la Pitié-Salpétrière | Paris, France | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05462613